Introduction
============

Previously metastasis was a predictor of patient mortality; however, advances in the current understanding of cancer biology have enabled the cure or control of various malignancies and improved the prognosis and quality of life for patients ([@b1-ol-0-0-5456],[@b2-ol-0-0-5456]). Surgery and radiotherapy are used for local control and chemotherapy is used for systemic control ([@b1-ol-0-0-5456]--[@b3-ol-0-0-5456]). Through the application of these treatments, certain types of cancer may be cured; however, various specific types of cancer contain numerous hypoxic cancer cells and antioxidant enzymes that may confer resistance to radiotherapy ([@b1-ol-0-0-5456]--[@b3-ol-0-0-5456]). In addition to increasing tissue oxygen concentrations, it is important to inactivate antioxidant enzymes, including peroxidase and catalase, which protect cancer cells from oxidative stress ([@b1-ol-0-0-5456]--[@b10-ol-0-0-5456]). Hydrogen peroxide is able to inactivate antioxidant enzymes and produce oxygen when applied topically to cancer tissues ([@b1-ol-0-0-5456]--[@b3-ol-0-0-5456]). By adding hyaluronic acid to hydrogen peroxide the decomposition of hydrogen peroxide is delayed, and a high oxygen concentration is maintained in the cancer tissues for over 24 h ([@b1-ol-0-0-5456]--[@b3-ol-0-0-5456]). As reported in our previous studies ([@b5-ol-0-0-5456],[@b9-ol-0-0-5456],[@b10-ol-0-0-5456]), a novel radiosensitizer, Kochi Oxydol Radiation Therapy for Unresectable Carcinomas II (KORTUC II), was developed for the treatment of cancers that contain numerous hypoxic cancer cells and antioxidant enzymes. The components of KORTUC II are sodium hyaluronate 0.83% w/v and hydrogen peroxide 0.5% w/v. The concept of KORTUC II is to transform radioresistant cancer into radiosensitive cancer ([@b9-ol-0-0-5456],[@b10-ol-0-0-5456]). Following KORTUC II therapy, hypoxic and radioresistant cancer cells become hyperoxic and radiosensitive ([Figure 1](#f1-ol-0-0-5456){ref-type="fig"}). In our previous studies, the efficacy of KORTUC II in the treatment of supraclavicular lymph node metastates and recurrent breast cancers was demonstrated in humans ([@b9-ol-0-0-5456],[@b10-ol-0-0-5456]). The aim of the current study is to evaluate the safety and effectiveness of KORTUC II in patients with stage IV primary breast cancer, following induction chemotherapy with epirubicin combined with cyclophosphamide and paclitaxel or docetaxel.

Materials and methods
=====================

### KORTUC II formulation

Hyaluronic acid preparation (2.5 ml) with 1% w/v sodium hyaluronate (ARTZ Dispo^®^; Seikagaku Corporation, Tokyo, Japan) was present in each dose. This was composed of 25 mg sodium hyaluronate, 2.5 mg L-methionine (Kaken Pharmaceutical Co., Ltd., Tokyo, Japan), sodium chloride, potassium phosphate, crystalline sodium dihydrogen phosphate and an isotonizing agent, sodium hyaluronate (Kaken Pharmaceutical Co., Ltd.). The preparation was a colorless, transparent, viscous and aqueous solution with a pH of 6.8--7.8, a specific osmotic pressure of 1.0--1.2 (relative to physiological saline) and an average molecular weight of 0.6--1.2 million. Immediately prior to administration, 0.5 ml hydrogen peroxide 3% w/v solution (Oxydol; Ken-ei Pharmaceutical Co., Ltd., Osaka, Japan) was added to the solution. The final solution of the radiosensitizer had a sodium hyaluronate concentration of \~0.83% and a hydrogen peroxide concentration of \~0.5%. The radiosensitizer solution was the same as the solution administered for the treatment of chemotherapy-resistant supraclavicular lymph node metastates and recurrent breast cancers in our previous studies ([@b9-ol-0-0-5456],[@b10-ol-0-0-5456]).

The recruitment of patients for the present study was conducted between November 2006 and January 2011 at the Kochi Medical School Hospital (Kochi, Japan). The institutional ethics committee of Kochi University approved the use of KORTUC II for the treatment of patients with stage IV primary breast cancer. Seven patients with stage IV primary breast cancer were enrolled in the current study and provided written, informed consent. The criteria for case selection included a patient age of 20--80 years, and the patient and their families had opted for the KORTUC II treatment. The ages of the patients ranged from 36--65 years (mean average age, 56 years). Localized management of the lesions was determined to be problematic using regular chemotherapy or radiotherapy. Prior to and following KORTUC II treatment, chemotherapy including epirubicin (Nippon Kayaku, Tokyo, Japan), cyclophosphamide (Shionogi & Co., Ltd., Osaka, Japan), fluorouracil (Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan), epirubicin combined with cyclophosphamide, or docetaxel hydrate (Elmed Eisai Co., Ltd., Tokyo, Japan) was administered to prevent disease progression. The numbers of cycles of chemotherapy prior to KORTUC II therapy are shown in [Table I](#tI-ol-0-0-5456){ref-type="table"}. Combinations of systemic chemotherapy were selected according to updated guidelines for breast cancer treatment.

KORTUC II treatment was administered for the local control of breast cancer and chemotherapy was performed for systemic control. The radiotherapy regimen consisted of 2.75 Gy/fraction, 5 fractions/week for a total of 16--18 fractions and a total radiation dose of 44--49.5 Gy. For two patients (designated 6 and 7), boost irradiation (3 Gy/fraction, 3 fractions) was administered to control the site of the primary lesions; irradiation by X-ray for the target lesion was performed by tangential irradiation. The energy level of the X-ray was 4 MV, and the energy level of the electron beam was 15 MeV. The KORTUC II agent was composed of 2.5 ml 1% w/v sodium hyaluronate and 0.5 ml 3% w/v hydrogen peroxide. The administration of 3--6 ml KORTUC II was initiated following the sixth radiation fraction and performed twice a week under ultrasonographic guidance in order to maintain a high oxygen concentration in the cancerous tissues for 48 h based on our previous experimental and studies ([@b1-ol-0-0-5456]--[@b10-ol-0-0-5456]). The volume of the KORTUC II administered to each patient was adjusted according to the respective tumor diameter evaluated based on imaging modalities such as ultrasonographic studies and/or computed tomography ([@b5-ol-0-0-5456]). The total number of injections/patient was 5--6. The clinical features and therapeutic effects observed in each patient are presented in [Table I](#tI-ol-0-0-5456){ref-type="table"}.

### Assessment of the therapeutic response to KORTUC II treatment

The majority of the patients included in the current study underwent positron emission tomography-computed tomography (PET-CT) examinations prior to, and 1--7 months following, KORTUC II treatment. The therapeutic effects were evaluated by comparison of the pre-treatment and post-treatment PET-CT scans of the local tissues subjected to KORTUC II therapy. The patients subsequently underwent PET-CT examinations every six months when possible for at least three years, following the conclusion of KORTUC II treatment. The final therapeutic response of the lesion was assessed according to the Revised Response Evaluation Criteria in Solid Tumors guidelines (version 1.1) and patient follow-ups and tumor assessments were performed once a month following KORTUC II therapy. Each patient was assigned a toxicity grade using the National Institutes of Health Common Toxicity Criteria ([@b9-ol-0-0-5456],[@b10-ol-0-0-5456]). To evaluate the feasibility of KORTUC II treatment, all treatment-associated complications were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE; version 4.0) ([@b9-ol-0-0-5456],[@b10-ol-0-0-5456]). Patient follow-ups were conducted for ≥15 months ([@b1-ol-0-0-5456]--[@b3-ol-0-0-5456]).

Results
=======

KORTUC II treatment was completed with tolerable adverse effects. Four patients (57%) exhibited the acute phase complications of local erosion or ulceration in the treated tissues and required professional dermatological treatment \[patient (Pt.)2, Pt.3, Pt.4 and Pt.5\]. These complications were considered to be causally associated with tumor shrinkage induced by KORTUC II treatment. The aforementioned patients were determined to have CTCAE grade IV complications. Three patients (43%) experienced soreness and depilation in the treated tissues (Pt.1, Pt.6 and Pt.7) and were determined to have CTCAE grade II complications. All the complications exhibited by the patients were cured by local treatment and are presented in [Fig. 2](#f2-ol-0-0-5456){ref-type="fig"}. None of the patients were observed to develop chronic complications during the present study.

Of the seven patients, five (71%) exhibited a complete response, two (29%) demonstrated a partial response and none of the patients exhibited stable or progressive disease; thus, the response rate was 100%. The overall survival rate was 100% at 1 year, 86% (6/7) at 2 years and 71% (5/7) at 3 years. The local control rate was 100% at 1 year (7/7), 2 years (6/6) and 3 years (5/5). The disease-free survival rate was 86% (6/7) at 1 year, 50% (3/6) at 2 years and 40% (2/5) at 3 years ([Table II](#tII-ol-0-0-5456){ref-type="table"}).

The treatment outcomes were satisfactory and the adverse effects were determined to be within an acceptable range. Representative PET-CT examinations are presented in [Fig. 3](#f3-ol-0-0-5456){ref-type="fig"}. Although new metastatic lesions were detected in four patients during follow-up, overall the lesions were ameliorated by the appropriate treatment. The mean follow-up period by December 2014 was 51 months; four patients have succumbed to the disease at the time of writing.

Discussion
==========

Improvements in diagnostic methods have facilitated the earlier detection of numerous types of primary cancer, recurrent cancer and metastases, and previous advances in chemotherapy have been notable. For metastatic or unresectable cancer, combination chemotherapy and radiotherapy (chemoradiotherapy) is typically administered with good therapeutic outcomes ([@b11-ol-0-0-5456]--[@b21-ol-0-0-5456]). The results of our previous studies ([@b9-ol-0-0-5456],[@b10-ol-0-0-5456]) regarding the use of KORTUC II for the treatment of supraclavicular lymph node metastates and recurrent breast cancers indicated comparable efficacy to treatment with chemoradiotherapy. Although the present study utilized alternative evaluation and timing methods, the effect of KORTUC II for the treatment of local lesions in patients with stage IV breast cancer, following induction chemotherapy, revealed similar treatment outcomes compared with chemoradiotherapy ([@b11-ol-0-0-5456]--[@b21-ol-0-0-5456]). The response rate (100%) and the overall survival rate at 1 year (100%), 2 years (85%) and 3 years (71%) were good, and the treatment regimen was well tolerated. Certain patients exhibited severe side effects in the treated tissues, which was possibly due to tumor shrinkage induced by KORTUC II. Although metastasis was observed during patient examinations following the conclusion of the treatment, the majority of the lesions were improved. The results indicate that KORTUC II treatment outcomes are satisfactory with adverse effects within an acceptable range, particularly for stage IV primary breast cancer following induction chemotherapy. Though the numbers of the patients treated with KORTUC II in the individual studies are small, good therapeutic effects of KORTUC II have also been reported in other studies ([@b1-ol-0-0-5456]--[@b8-ol-0-0-5456]). Therefore, KORTUC II may be a novel therapeutic treatment for patients with breast cancer ([@b3-ol-0-0-5456],[@b4-ol-0-0-5456],[@b6-ol-0-0-5456],[@b8-ol-0-0-5456]). KORTUC II consists of sodium hyaluronate 0.83% w/v and hydrogen peroxide 0.5% w/v, which are inexpensive and readily available. The mechanism of action of KORTUC II is simple ([@b9-ol-0-0-5456],[@b10-ol-0-0-5456]), involving inactivation of peroxidase/catalase and production of oxygen in the target tumor tissue simultaneously, and deep lesions are accessible to treatment through the use of a Cathelin needle to administer the radiosensitizer under ultrasonographic guidance.

Therefore, the novel radiosensitizer KORTUC II may be used for the treatment of certain types of cancer. However, the number of patients currently and previously treated with KORTUC II, and the respective follow-up periods, is too small for a definitive conclusion. Further randomized clinical trials with a larger sample size are required to establish the therapeutic efficacy of KORTUC II.
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![The mechanism of action for the novel radiosensitizer KORTUC II. Antioxidant enzymes in the tumors are inactivated and plentiful oxygen is produced; in this way, radioresistant cancers can be made radiosensitive. KORTUC II, Kochi Oxydol Radiation Therapy for Unresectable Carcinomas II.](ol-13-01-0069-g00){#f1-ol-0-0-5456}

![Representative complications observed in the treated tissues of patient number 4 (58-year-old female with stage IV primary breast cancer). The patient was selected due to the presence of characteristic complications. (A) 10 days following the KORTUC II treatment, erosion surrounded by ulcers was observed at the right axilla. Gentamicin sulfate ointment was applied to treat the erosion and clobetasol propionate ointment was applied for the red spots. (B) 15 days following KORTUC II treatment, the erosion and the red spots are markedly improved. (C) 20 days following KORTUC II treatment. Re-epithelialization was observed at the lesion site and recurrence of the lesion was not observed. KORTUC II, Kochi Oxydol Radiation Therapy for Unresectable Carcinomas II.](ol-13-01-0069-g01){#f2-ol-0-0-5456}

###### 

Therapeutic response following KORTUC II treatment as evaluated by PET-CT examination of patient number 4 (58-year-old female with stage IV primary breast cancer). (A) PET-CT prior to induction chemotherapy with epirubicin and cyclophosphamide. Numerous lymph node and skin metastases are depicted. (B) PET-CT prior to KORTUC II treatment. With induction chemotherapy, FDG accumulation in the right breast and right axilla improved and the skin metastases disappeared. KORTUC II, Kochi Oxydol Radiation Therapy for Unresectable Carcinomas II; PET-CT, positron emission tomography-computed tomography; FDG, fluorodeoxyglucose. (C) Four months following KORTUC II treatment. FDG accumulation in the left breast and in the chest disappeared. (D) PET-CT seven months following KORTUC II treatment. FDG accumulation had not recurred on the PET-CT scan conducted (E) 16 months following KORTUC II treatment. KORTUC II, Kochi Oxydol Radiation Therapy for Unresectable Carcinomas II; PET-CT, positron emission tomography-computed tomography; FDG, fluorodeoxyglucose. PET-CT scans conducted (F) 21 months, (G) 26 months and (H) 32 months following KORTUC II treatment. KORTUC II, Kochi Oxydol Radiation Therapy for Unresectable Carcinomas II; PET-CT, positron emission tomography-computed tomography. PET-CT scans conducted (I) 38 months, (J) 49 months and (K) 64 months following KORTUC II treatment. KORTUC II, Kochi Oxydol Radiation Therapy for Unresectable Carcinomas II; PET-CT, positron emission tomography-computed tomography. PET-CT scan conducted (L) 76 months following KORTUC II treatment. FDG accumulation and recurrence of metastasis were not observed during follow-up. Prior to treatment, the size of the right breast tumor was 28 mm and the SUVmax of FDG accumulation was 8.6. The target lesion and the FDG accumulation had disappeared four months following KORTUC II treatment, as determined by a PET-CT scan. The therapeutic effect was determined to be a complete response in patient number 4. KORTUC II, Kochi Oxydol Radiation Therapy for Unresectable Carcinomas II; PET-CT, positron emission tomography-computed tomography; FDG, fluorodeoxyglucose; SUVmax, max value of the standardized uptake value.
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###### 

Patient clinical and therapeutic data.

  Pt.   Age (y)   Metastatic area             Induction chemotherapy   Treatment area (KORTUC II field)   FDG accumulation                                      Tumor size (mm)                                          Therapeutic effect
  ----- --------- --------------------------- ------------------------ ---------------------------------- ----------------------------------------------------- -------------------------------------------------------- -------------------------------------------------
  1     63        Bone, lung and lymph node   PTX × 15                 Left breast                        5.6→D^[a](#tfn1-ol-0-0-5456){ref-type="table-fn"}^    14→10                                                    PR
  2     57        Lymph node and skin         FEC × 8                  Left breast                        7.7→D^[a](#tfn1-ol-0-0-5456){ref-type="table-fn"}^    28→D^[a](#tfn1-ol-0-0-5456){ref-type="table-fn"}^        CR^[b](#tfn2-ol-0-0-5456){ref-type="table-fn"}^
  3     65        Bone, lung and lymph node   EC × 6                   Left breast                        11.2→D^[a](#tfn1-ol-0-0-5456){ref-type="table-fn"}^   15→3                                                     CR^[b](#tfn2-ol-0-0-5456){ref-type="table-fn"}^
  4     58        Lymph node and skin         EC × 3                   Right breast                       8.6→D^[a](#tfn1-ol-0-0-5456){ref-type="table-fn"}^    28→14                                                    CR^[b](#tfn2-ol-0-0-5456){ref-type="table-fn"}^
  5     55        Lung                        EC × 3                   Left breast                        6.2→2.2                                               28→22                                                    PR
  6     36        Lymph node                  FEC × 4 and PTX × 12     Right breast                       No data→2.5                                           No data→D^[a](#tfn1-ol-0-0-5456){ref-type="table-fn"}^   CR^[b](#tfn2-ol-0-0-5456){ref-type="table-fn"}^
  7     51        Bone                        EC × 9 and TXT × 6       Left breast                        5.1→D^[a](#tfn1-ol-0-0-5456){ref-type="table-fn"}^    23→D^[a](#tfn1-ol-0-0-5456){ref-type="table-fn"}^        CR^[b](#tfn2-ol-0-0-5456){ref-type="table-fn"}^

D was defined as the disappearance of cancer shadows following CT examination.

The criteria for CR was the dissipation of FDG accumulation as determined by PET-CT or the tumor lesion as determined by CT. RT field, radiation therapy field; CR, complete response; PR, partial response; D, disappearance; X, x-ray; E, electron beam; PTX, paclitaxel; EC, epirubicin and cyclophosphamide; FEC, fluorouracil and epirubicin and cyclophosphamide; TXT, docetaxel hydrate; Pt, patient; KORTUC II, Kochi Oxydol Radiation Therapy for Unresectable Carcinomas II; FDG, fluorodeoxyglucose; PET-CT, positron emission tomography-computed tomography.

###### 

Patient treatment outcomes.

  Outcome                      1 year        2 years       3 years
  ---------------------------- ------------- ------------- -------------
  Overall survival rate        100% (7/7)      86% (6/7)     71% (5/7)
  Local control rate           100% (7/7)    100% (6/6)    100% (5/5)
  Disease-free survival rate     86% (6/7)     50% (3/6)     40% (2/5)
